<DOC>
	<DOCNO>NCT00389233</DOCNO>
	<brief_summary>The study carry randomised , single-blind , active-controlled , multi-centric , phase III study two parallel treatment group . The primary efficacy criterion frequency effective gut cleanse two treatment group ( grade A B `` overall quality gut cleanse '' judge blind expert panel basis videotape record endoscopic procedure ) .</brief_summary>
	<brief_title>A Phase III Trial Assess Efficacy , Acceptability Safety MoviprepÂ® Versus 4L PEG+E Standard Solution</brief_title>
	<detailed_description>The study design randomise , active-controlled , single-blind , multi-centre , pivotal phase III trial two parallel treatment group . 15 German hospital specialise gastroenterology unit expect participate investigation . Up 360 hospital in-patients routinely schedule undergo complete colonoscopy enrol one two day prior endoscopic procedure , randomly allocate one two treatment arm ratio 1:1 . Bowel preparation perform use equal split dose either low-volume NRL994 ( two dose 1,000 mL ) high-volume PEG+E ( two dose 2,000 mL ) . The first dose take evening procedure , second dose morning day colonoscopy . The patient allocate NRL994 ask drink least 1L additional clear liquid addition study drug . During colonoscopy cleanse five pre-defined gut segment assess physician performing examination , use 5-level verbal rating scale . Videotapes record procedure order allow central review blind independent expert panel whose rating primary basis analysis efficacy . The patient enrol study ask fill questionnaire concern acceptability preparation . A patient 's participation study terminate upon completion intervention perform final examination fill study termination page . No interim analysis perform .</detailed_description>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Polyethylene glycol 3350</mesh_term>
	<criteria>write informed consent prior inclusion ; male female inpatient , age 18 85 year , indication complete colonoscopy ; willing able complete entire procedure comply study instruction ; female childbearing potential employ adequate method contraception . ileus ; intestinal obstruction perforation ; toxic megacolon ; congestive heart failure ( NYHA class III IV ) ; acute lifethreatening cardiovascular disease ; untreated uncontrolled arterial hypertension ( SBP max &gt; 170mmHg , DBP min &gt; 100mmHg ) ; severe renal failure ; severe liver failure ; know glucose6phosphatase dehydrogenase deficiency ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>